Manulife (Manufacturers Life Insurance)’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8M | Sell |
117,093
-16,791
| -13% | -$2.9M | 0.02% | 606 |
|
|
2025
Q4 | $23.7M | Buy |
133,884
+1,167
| +0.9% | +$163K | 0.02% | 597 |
|
|
2025
Q3 | $16.1M | Sell |
132,717
-1,106
| -0.8% | -$125K | 0.01% | 688 |
|
|
2025
Q2 | $14M | Buy |
133,823
+110,972
| +486% | +$11.8M | 0.01% | 712 |
|
|
2025
Q1 | $2.67M | Buy |
22,851
+534
| +2% | +$60.8K | ﹤0.01% | 1387 |
|
|
2024
Q4 | $1.89M | Sell |
22,317
-306
| -1% | -$28.1K | ﹤0.01% | 1592 |
|
|
2024
Q3 | $2.03M | Sell |
22,623
-278
| -1% | -$24.3K | ﹤0.01% | 1541 |
|
|
2024
Q2 | $1.84M | Buy |
22,901
+999
| +5% | +$74K | ﹤0.01% | 1525 |
|
|
2024
Q1 | $1.75M | Sell |
21,902
-8,390
| -28% | -$704K | ﹤0.01% | 1565 |
|
|
2023
Q4 | $2.41M | Buy |
30,292
+9,940
| +49% | +$665K | ﹤0.01% | 1413 |
|
|
2023
Q3 | $1.42M | Buy |
20,352
+6,878
| +51% | +$514K | ﹤0.01% | 1552 |
|
|
2023
Q2 | $968K | Buy |
13,474
+451
| +3% | +$33.3K | ﹤0.01% | 1678 |
|
|
2023
Q1 | $803K | Buy |
13,023
+35
| +0.3% | +$2.3K | ﹤0.01% | 1733 |
|
|
2022
Q4 | $1M | Buy |
12,988
+1,157
| +10% | +$69.2K | ﹤0.01% | 1605 |
|
|
2022
Q3 | $528K | Buy |
11,831
+40
| +0.3% | +$2K | ﹤0.01% | 1945 |
|
|
2022
Q2 | $452K | Buy |
11,791
+157
| +1% | +$4.96K | ﹤0.01% | 2119 |
|
|
2022
Q1 | $482K | Sell |
11,634
-2,865
| -20% | -$88.8K | ﹤0.01% | 2230 |
|
|
2021
Q4 | $548 | Sell |
14,499
-414
| -3% | -$15.2K | ﹤0.01% | 2203 |
|
|
2021
Q3 | $492K | Sell |
14,913
-950
| -6% | -$37K | ﹤0.01% | 2299 |
|
|
2021
Q2 | $1.07M | Buy |
15,863
+25
| +0.2% | +$1.5K | ﹤0.01% | 1954 |
|
|
2021
Q1 | $897K | Sell |
15,838
-899
| -5% | -$63.2K | ﹤0.01% | 1955 |
|
|
2020
Q4 | $1.36M | Buy |
16,737
+603
| +4% | +$45.1K | ﹤0.01% | 1674 |
|
|
2020
Q3 | $1.15M | Sell |
16,134
-470
| -3% | -$36.6K | ﹤0.01% | 1601 |
|
|
2020
Q2 | $1.27M | Sell |
16,604
-417
| -2% | -$32.1K | ﹤0.01% | 1532 |
|
|
2020
Q1 | $1M | Buy |
17,021
+1,704
| +11% | +$139K | ﹤0.01% | 1516 |
|
|
2019
Q4 | $1.58M | Sell |
15,317
-179
| -1% | -$7.23K | ﹤0.01% | 1484 |
|
|
2019
Q3 | $342K | Buy |
15,496
+834
| +6% | +$21.4K | ﹤0.01% | 2242 |
|
|
2019
Q2 | $378K | Buy |
+14,662
| New | +$294K | ﹤0.01% | 2216 |
|
|
2017
Q3 | – | Sell |
-492
| Closed | -$3K | – | 4241 |
|
|
2017
Q2 | $3K | Sell |
492
-41
| -8% | -$172 | ﹤0.01% | 4031 |
|
|
2017
Q1 | $2K | Hold |
533
| – | – | ﹤0.01% | 3929 |
|
|
2016
Q4 | $4K | Hold |
533
| – | – | ﹤0.01% | 3965 |
|
|
2016
Q3 | $4K | Hold |
533
| – | – | ﹤0.01% | 3912 |
|
|
2016
Q2 | $4K | Hold |
533
| – | – | ﹤0.01% | 3850 |
|
|
2016
Q1 | $5K | Buy |
+533
| New | +$4.89K | ﹤0.01% | 3774 |
|
Other funds holding AXSM
VPM
VCM
DTC
Manulife (Manufacturers Life Insurance)'s AXSM Position: Q1 2026 in Review
Manulife (Manufacturers Life Insurance) reduced its Axsome Therapeutics (AXSM) stake by 13% in Q1 2026, selling an estimated $2.9M and leaving 117,093 shares worth $19.8M. The position accounts for 0.02% of the portfolio, ranked #606.
Manulife (Manufacturers Life Insurance) first reported a position in AXSM in Q1 2016 and has held it in 34 quarters since. The position peaked at $23.7M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Manulife (Manufacturers Life Insurance) held 117,093 shares of Axsome Therapeutics worth $19.8M as of Q1 2026.
- Manulife (Manufacturers Life Insurance) sold 16,791 Axsome Therapeutics shares in Q1 2026, an estimated $2.9M.
- Axsome Therapeutics made up 0.02% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #606 holding.
- Manulife (Manufacturers Life Insurance) first reported a position in Axsome Therapeutics in Q1 2016 and has held it in 34 quarters since.
- Manulife (Manufacturers Life Insurance)'s Axsome Therapeutics position peaked at $23.7M in Q4 2025.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.